Search Results

Search

Ethics Talk: Health Hazards of Cost Sharing

Submitted by Audiey.Kao@ama… on

In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Ziad Obermeyer about the potential impact on mortality of cost-sharing practices of health insurers.

Click here to read the transcript. 

Ziad Obermeyer, MD, MPhil is the Blue Cross of California Distinguished Associate Professor of Health Policy and Management, UC Berkeley School of Public Health.

Video

Recorded on March 9, 2021

 

Audio

 

Conflict of Interest Disclosure
Interviewee reports having equity stakes in Deep Health Dandelion Health and Berkeley Data Ventures as well as receiving speaking and consulting fees from Independence Blue Cross and Anthem.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Header Image image Issue Racial and Ethnic Health Equity in the US: Part 2 CME Off

Ethics Talk: Antibiotic Stewardship During COVID

Submitted by Audiey.Kao@ama… on

In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Olivia Kates about appropriate use of antibiotics during the COVID-19 pandemic.

Click here to read the transcript.

Olivia Kates, MD is a third-year fellow in infectious diseases at the University of Washington in Seattle. 

Video

Recorded on May 17, 2021

Infectious Disease Medical Knowledge Patient Care

Audio

 

Conflict of Interest Disclosure
Interviewee had no conflicts of interest to disclose.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Header Image image Issue Ending the HIV Epidemic Off

Ethics Talk: Could Trusting Science Mean Not Trusting Some FDA Decisions?

Submitted by Audiey.Kao@ama… on

In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Caleb Alexander about the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.

Click here to read the transcript.

G. Caleb Alexander, MD, MS is professor of epidemiology and medicine at Johns Hopkins Bloomberg School of Public Health.

Video

Recorded on June 22, 2021

 

Neurology Patient Care

Audio

 

Conflict of Interest Disclosure

Dr Alexander is past chair and current member of FDA's Peripheral and Central Nervous System Drugs Advisory Committee. He is a co-founding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. He was also a member of OptumRx's National Pharmacy and Therapeutics Committee.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Header Image image Issue Visibility and Measurability in Health Care Off
Medical Education
Jul 2016

Medical Education and Global Health Equity

Peter Drobac, MD, MPH and Michelle Morse, MD, MPH
The University of Global Health Equity aims to provide the tools and technology to develop the skills students need to improve fragile health systems.
AMA J Ethics. 2016; 18(7):702-709. doi: 10.1001/journalofethics.2016.18.7.medu1-1607.
Case and Commentary
Oct 2018

How Should Physicians Help Patients Who Are Ill Because They Work in Agriculture?

Nicole Civita, JD, LLM
Farmworkers can become ill due to toxic exposure in their work environments. Recommending specific restrictions, educating patients on protection strategies, and partnering with agribusiness owners and allied health workers can drive development of alternatives to agricultural practices with health risks.
AMA J Ethics. 2018; 20(10):E932-940. doi: 10.1001/amajethics.2018.932.
Case and Commentary
Sep 2019

How Should We Decide Whether and When Some Care Is Better Than No Care?

Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019; 21(9):E729-734. doi: 10.1001/amajethics.2019.729.
Case and Commentary
Oct 2019

How Should We Determine the Value of CAR T-Cell Therapy?

Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019; 21(10):E844-851. doi: 10.1001/amajethics.2019.844.